HLS Therapeutics Inc.
HLTRF
$3.47
-$0.07-2.06%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.92% | -4.20% | -6.61% | -10.23% | -9.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.92% | -4.20% | -6.61% | -10.23% | -9.46% |
| Cost of Revenue | 9.63% | 9.68% | 12.67% | 11.08% | 15.75% |
| Gross Profit | -5.81% | -8.62% | -12.23% | -15.87% | -15.65% |
| SG&A Expenses | -14.14% | -11.36% | -9.23% | -4.80% | -11.58% |
| Depreciation & Amortization | -10.45% | -19.40% | -24.99% | -28.87% | -27.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.55% | -10.16% | -11.54% | -12.42% | -14.17% |
| Operating Income | 45.33% | 46.56% | 39.72% | 25.73% | 36.39% |
| Income Before Tax | 23.03% | 27.43% | 50.52% | 43.96% | 38.04% |
| Income Tax Expenses | -92.94% | -93.37% | 1,662.84% | 1,597.43% | 1,019.23% |
| Earnings from Continuing Operations | 35.92% | 37.55% | 35.41% | 28.61% | 22.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.92% | 37.55% | 35.41% | 28.61% | 22.85% |
| EBIT | 45.33% | 46.56% | 39.72% | 25.73% | 36.39% |
| EBITDA | 8.42% | -4.20% | -16.65% | -30.38% | -21.63% |
| EPS Basic | 21.18% | 23.96% | 23.17% | 16.03% | 21.71% |
| Normalized Basic EPS | 18.06% | 15.09% | 5.12% | -2.61% | 9.10% |
| EPS Diluted | 19.47% | 22.38% | 22.01% | 15.01% | 21.67% |
| Normalized Diluted EPS | 18.06% | 15.09% | 5.12% | -2.61% | 9.10% |
| Average Basic Shares Outstanding | -1.69% | -1.74% | -2.16% | -2.37% | -1.46% |
| Average Diluted Shares Outstanding | -1.69% | -1.74% | -2.16% | -2.37% | -1.46% |
| Dividend Per Share | -- | -- | -- | -- | -98.41% |
| Payout Ratio | -- | -- | -- | -- | 1.00% |